Apraclonidine and the treatment of glaucoma

Apraclonidine hydrochloride is the most recently FDA-approved α₂-adrenergic agonist for use in glaucoma. Early trials have focused on apraclonidine's effectiveness in treating short-term intraocular pressure elevations, including postlaser and surgical procedures. Early studies indicate that apraclonidine may be beneficial in long-term use also. The literature regarding short- and long-term use of apraclonidine is reviewed.